Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Neuroblastoma 1

Interventions

Specimen Handling 128Magnetic Resonance Spectroscopy 105Biopsy 76pembrolizumab 63Nivolumab 60Carboplatin 59Cisplatin 57Cyclophosphamide 53Paclitaxel 44Radiotherapy 36Bevacizumab 36Gemcitabine 34Dexamethasone 33Rituximab 26Doxorubicin 26olaparib 25Pemetrexed 25Fluorouracil 25atezolizumab 24Radiation 24Injections 23Docetaxel 23fludarabine 22durvalumab 22Vincristine 21Prednisone 21Oxaliplatin 21Ipilimumab 21Cytarabine 21venetoclax 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × 3-Iodobenzylguanidine × 30 days × Clear all
NCT00107289 2026-05-29

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
200 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡